LLY - ELI LILLY & Co
1076.98
5.340 0.496%
Share volume: 932,804
Last Updated: 12-24-2025
Pharmaceutical Products/Pharmaceutical Preparations:
-0.12%
PREVIOUS CLOSE
CHG
CHG%
$1,071.64
5.34
0.01%
Fundamental analysis
59%
Profitability
75%
Dept financing
22%
Liquidity
37%
Performance
57%
Performance
5 Days
0.05%
1 Month
-2.48%
3 Months
48.64%
6 Months
35.45%
1 Year
35.62%
2 Year
88.72%
Key data
Stock price
$1,076.98
DAY RANGE
$1,072.71 - $1,085.73
52 WEEK RANGE
$623.78 - $1,111.99
52 WEEK CHANGE
$37.52
DIVIDEND
$1.73
EX-DIVIDEND DATE
02-13-2026
NEXT EARNINGS DATE
08-07-2025
Company detail
CEO: David A. Ricks
Region: US
Website: lilly.com
Employees: 39,000
IPO year: 1972
Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Region: US
Website: lilly.com
Employees: 39,000
IPO year: 1972
Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic colorectal cancer, and hepatocellular carcinoma. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic ax
Recent news